METTL2 Inhibitors

METTL2 inhibitors encompass a range of chemical compounds that can interfere with the enzymatic activity of METTL2, a methyltransferase involved in tRNA methylation. These inhibitors can be classified based on their mechanism of inhibition, which includes competition with the methyl donor S-adenosylmethionine (SAM), direct binding to the active site of the enzyme, or indirect effects on the enzyme's function through alterations in chromatin structure and gene expression. Oxidized adenosine analogs, such as Adenosine Periodate Oxidized, can inhibit METTL2 by binding to the SAM site, preventing methyl group transfer. Sinefungin, a nucleoside analog, mimics SAM, occupying the enzyme's active site and blocking its activity. Similarly, 5'-Methylthioadenosine competes with SAM, hindering the methyl transfer process. Neplanocin A, a cyclic adenosine analog, and 3-Deazaneplanocin A, a potent inhibitor of S-adenosyl-L-homocysteine hydrolase, can inhibit METTL2 by affecting the availability and metabolism of SAM.

Some inhibitors, such as Decitabine and RG-108, can inhibit METTL2 by becoming integrated into RNA or binding to the enzyme's active site, respectively, impacting the enzyme's ability to interact with its substrates. BIX-01294 and Chaetocin, known for inhibiting histone methyltransferases, may affect METTL2 by modifying the chromatin landscape, which could influence METTL2's access to its tRNA substrates. EPZ004777, although a selective DOT1L inhibitor, may also have an impact on METTL2 by altering gene expression and possibly affecting the enzyme's regulatory mechanisms. Additionally, compounds like MTA and Furamidine can inhibit methyltransferases by competing with SAM or by intercalating into DNA, whichcan disrupt the transcription and methylation process, leading to indirect inhibition of METTL2. These inhibitors, while diverse in structure and mechanism, share the common feature of disrupting the normal function of METTL2 by impeding its ability to methylate tRNA, either through direct inhibition or through effects on related cellular pathways.